Home » Authors » Jim Shrine

Articles by Jim Shrine

European Sector Rallying Cry: Comebacks, Consolidation

March 12, 2003

Companies Urged To Shore Up Until Sector Regains Favor

Sep. 11, 2002

Companies Urged To Shore Up Until Sector Regains Favor

Sep. 11, 2002

European Biotech Struggling, Industry Waiting For Upswing

Sep. 10, 2002

European Biotech Struggling, Industry Waiting For Upswing

Sep. 10, 2002

Finding Hot’ Biotech Investments Still Means Looking At Leaders

March 21, 2002

Finding Hot’ Biotech Investments Still Means Looking At Leaders

March 21, 2002

Investors In Tight Market Looking At Hybrid Platform/Product Firms

March 20, 2002

Investors In Tight Market Looking At Hybrid Platform/Product Firms

March 20, 2002

Large-Cap Companies Doing Well In Maturing Industry s Bifurcation

Jan. 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...